BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Clinical Outcome
38 results:

  • 1. Low grade oncocytic renal tumor (LOT): Clinicopathological characterization of 13 cases.
    Almutairi F; Xu B
    Pathol Res Pract; 2024 Feb; 254():155127. PubMed ID: 38241777
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
    Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. KIF2C promotes clear cell renal cell carcinoma progression via activating JAK2/STAT3 signaling pathway.
    Deng H; Gong X; Ji G; Li C; Cheng S
    Mol Cell Probes; 2023 Dec; 72():101938. PubMed ID: 37863123
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma.
    Zhang ZC; Liu YF; Xi P; Nie YC; Sun T; Gong BB
    Hereditas; 2023 Jan; 160(1):1. PubMed ID: 36635779
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Identification of an independent immune-genes prognostic index for renal cell carcinoma.
    Li G; Wei X; Su S; Wang S; Wang W; Wang Y; Meng X; Xia J; Song N; Qin C
    BMC Cancer; 2021 Jun; 21(1):746. PubMed ID: 34187413
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. ID1 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Deterioration of Clear Cell Renal Cell Carcinoma.
    Qiu X; Gu Y; Ni Y; Li Q
    Biomed Res Int; 2020; 2020():2064582. PubMed ID: 33178820
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets.
    Verbiest A; Van Hoef V; Rodriguez-Antona C; García-Donas J; Graña-Castro O; Albersen M; Baldewijns M; Laenen A; Roussel E; Schöffski P; Wozniak A; Caruso S; Couchy G; Zucman-Rossi J; Beuselinck B
    PLoS One; 2020; 15(9):e0238809. PubMed ID: 32915890
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The prognostic value and potential subtypes of immune activity scores in three major urological cancers.
    Shi B; Qi J
    J Cell Physiol; 2021 Apr; 236(4):2620-2630. PubMed ID: 32853461
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Metabolic control of PPAR activity by aldehyde dehydrogenase regulates invasive cell behavior and predicts survival in hepatocellular and renal clear cell carcinoma.
    Andrejeva D; Kugler JM; Nguyen HT; Malmendal A; Holm ML; Toft BG; Loya AC; Cohen SM
    BMC Cancer; 2018 Nov; 18(1):1180. PubMed ID: 30486822
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
    Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W
    BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA.
    Kluzek K; Srebniak MI; Majer W; Ida A; Milecki T; Huminska K; van der Helm RM; Silesian A; Wrzesinski TM; Wojciechowicz J; Beverloo BH; Kwias Z; Bluyssen HAR; Wesoly J
    Oncotarget; 2017 Apr; 8(17):28558-28574. PubMed ID: 28212566
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma.
    Zheng J; Wang L; Peng Z; Yang Y; Feng D; He J
    EBioMedicine; 2017 Feb; 15():62-72. PubMed ID: 27993630
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Prognostic value of cross-omics screening for kidney clear cell renal cancer survival.
    Dimitrieva S; Schlapbach R; Rehrauer H
    Biol Direct; 2016 Dec; 11(1):68. PubMed ID: 27993167
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Tumor Infiltrating Mast Cells (TIMs) Confers a Marked Survival Advantage in Nonmetastatic Clear-Cell Renal Cell Carcinoma.
    Fu H; Zhu Y; Wang Y; Liu Z; Zhang J; Wang Z; Xie H; Dai B; Xu J; Ye D
    Ann Surg Oncol; 2017 May; 24(5):1435-1442. PubMed ID: 27896514
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma.
    Wang ZR; Wei JH; Zhou JC; Haddad A; Zhao LY; Kapur P; Wu KJ; Wang B; Yu YH; Liao B; He DL; Chen W; Margulis V; Hsieh JT; Luo JH
    Oncotarget; 2016 May; 7(21):31508-19. PubMed ID: 27129174
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib.
    Lu X; Gu W; Zhang H; Zhu Y; Shi G; Ye D
    Oncotarget; 2016 May; 7(18):26879-87. PubMed ID: 27058898
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma.
    Wei JH; Haddad A; Wu KJ; Zhao HW; Kapur P; Zhang ZL; Zhao LY; Chen ZH; Zhou YY; Zhou JC; Wang B; Yu YH; Cai MY; Xie D; Liao B; Li CX; Li PX; Wang ZR; Zhou FJ; Shi L; Liu QZ; Gao ZL; He DL; Chen W; Hsieh JT; Li QZ; Margulis V; Luo JH
    Nat Commun; 2015 Oct; 6():8699. PubMed ID: 26515236
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer.
    Pflueger D; Mittmann C; Dehler S; Rubin MA; Moch H; Schraml P
    BMC Genomics; 2015 Mar; 16(1):247. PubMed ID: 25888189
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.